Allstate Corporation’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.63M Buy
12,349
+5,195
+73% +$689K 0.02% 600
2025
Q4
$1.01M Buy
7,154
+3,786
+112% +$548K 0.01% 521
2025
Q3
$473K Buy
+3,368
New +$456K 0.01% 529
2025
Q2
Sell
-4,930
Closed -$545K 433
2025
Q1
$545K Buy
4,930
+2,021
+69% +$256K 0.02% 487
2024
Q4
$397K Buy
+2,909
New +$360K 0.01% 539
2023
Q1
Sell
-4,215
Closed -$503K 443
2022
Q4
$503K Buy
4,215
+1
+0% +$117 0.02% 495
2022
Q3
$448K Buy
4,214
+623
+17% +$63.2K 0.01% 518
2022
Q2
$350K Buy
+3,591
New +$331K 0.01% 556
2021
Q4
Sell
-3,522
Closed -$338K 754
2021
Q3
$338K Sell
3,522
-271
-7% -$25.6K 0.01% 601
2021
Q2
$369K Buy
3,793
+250
+7% +$24K 0.01% 600
2021
Q1
$345K Sell
3,543
-1,201
-25% -$126K 0.01% 638
2020
Q4
$455K Buy
4,744
+1,323
+39% +$128K 0.01% 536
2020
Q3
$329K Sell
3,421
-592
-15% -$68.5K 0.01% 546
2020
Q2
$490K Sell
4,013
-172
-4% -$19K 0.02% 442
2020
Q1
$362K Sell
4,185
-8,800
-68% -$861K 0.01% 438
2019
Q4
$1.4M Hold
12,985
0.03% 373
2019
Q3
$1.17M Buy
12,985
+210
+2% +$19.6K 0.02% 371
2019
Q2
$1.08M Buy
+12,775
New +$1.05M 0.02% 380

Other funds holding NBIX

Allstate Corporation's NBIX Position: Q1 2026 in Review

Allstate Corporation increased its Neurocrine Biosciences (NBIX) stake by 73% in Q1 2026, buying an estimated $689K and bringing the position to 12,349 shares worth $1.63M. The position accounts for 0.02% of the portfolio, ranked #600.

Allstate Corporation first reported a position in NBIX in Q2 2019 and has held it in 18 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Allstate Corporation held 12,349 shares of Neurocrine Biosciences worth $1.63M as of Q1 2026.
  • Allstate Corporation bought 5,195 Neurocrine Biosciences shares in Q1 2026, an estimated $689K.
  • Neurocrine Biosciences made up 0.02% of Allstate Corporation's portfolio in Q1 2026, its #600 holding.
  • Allstate Corporation first reported a position in Neurocrine Biosciences in Q2 2019 and has held it in 18 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Allstate Corporation's 13F filing for Q1 2026, filed 11 May 2026.